<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746067</url>
  </required_header>
  <id_info>
    <org_study_id>TS134-US101</org_study_id>
    <nct_id>NCT03746067</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects of Food on the Absorption of TS-134 Administered Orally to Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1a study involving single oral dose of TS-134 in healthy male and female
      subjects. The safety, tolerability and pharmacokinetics of single dose of TS-134 will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2015</start_date>
  <completion_date type="Actual">January 13, 2016</completion_date>
  <primary_completion_date type="Actual">January 13, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - Cmax</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - AUC(0-last)</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Area under the concentration vs. time curve from time zero to last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - tmax</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - t1/2</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - CL/F</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Apparent clearance following oral administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-134 Plasma Pharmacokinetic Profile - Vd/F</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 hours post-dose</time_frame>
    <description>Apparent volumes of distribution following oral administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TS-134 Cerebral Spinal Fluid (CSF) Pharmacokinetic Profile - Cmax</measure>
    <time_frame>Day 1: predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Maximum CSF concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-134 CSF Pharmacokinetic Profile - AUC(0-last)</measure>
    <time_frame>Day 1: predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Area under the CSF concentration vs. time curve from time zero to last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-134 CSF Pharmacokinetic Profile - tmax</measure>
    <time_frame>Day 1: predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Time to maximum CSF concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-134 CSF Pharmacokinetic Profile - t1/2</measure>
    <time_frame>Day 1: predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Apparent terminal elimination half-life (CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-134 CSF Pharmacokinetic Profile - CL/F</measure>
    <time_frame>Day 1: predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Apparent clearance (CSF) following oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-134 CSF Pharmacokinetic Profile - Vd/F</measure>
    <time_frame>Day 1: predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose</time_frame>
    <description>Apparent volumes of distribution (CSF) following oral administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TS-134</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-134</intervention_name>
    <description>5 mg, 10 mg, or 20 mg oral solution</description>
    <arm_group_label>TS-134</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched Placebo oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and female participants between 18 and 55 years of age

          -  Body weight greater than or equal to 45 kg

          -  Body Mass Index (BMI) greater than or equal to 18 and less than or equal to 30 kg/m^2

        Exclusion Criteria:

          -  Female participants who are pregnant, intend to become pregnant, or are breastfeeding

          -  Clinically significant abnormal physical examination, 12-lead electrocardiogram (ECG)
             OR cardiac telemetry prior to dosing.

          -  Significant history or presence of hepatic, renal, cardiovascular, pulmonary,
             gastrointestinal, hematological, locomotor, immunologic, ophthalmologic, metabolic or
             oncological disease.

          -  History or presence of psychiatric or neurologic disease or condition

          -  History of alcohol or drug abuse

          -  Any participant who currently uses or has used tobacco or tobacco-containing products
             for at least one month prior to screening

          -  Participated in strenuous exercise within 48 hours prior to study start (initial
             dosing) and/or are unwilling to avoid strenuous exercise at any time throughout the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical R&amp;D Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL - Early Phase Clinical Unit-Los Angeles</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TS-134, CSF</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

